Absci: When AI Meets Antibodies — and Insiders Can’t Resist Buying More!
AI is designing drugs, and Absci is leading the charge — with insider confidence, top-tier partners, and a cash runway through 2028. Still pre-revenue but packed with promise, this biotech might just be the next NVIDIA of antibodies.
Salesforce (CRM): Insider Buys, AI Clouds, and Customer Armies — Should You Join the Ride?
Salesforce insiders are buying, AI is booming, and institutions are all-in. But is CRM stock really ready to rebound — or just blowing more cloud smoke? ☁️💸